Daniel K Conners Race to Cure Cancer and One Mans Vision of Bio-Technology.
He could never have guessed the impact his work would have on the world of cancer treatment when Daniel K Conners started his humble bio-technology company from his home in the 1990s.
The entirely new cancer treatment envisioned by Conners so long ago is still being tested in the clinic, but the initial results are attracting serious attention from leading oncologists and pharmaceutical firms. This targeted immunotherapy drug works synergistically with monoclonal antibodies to take on innate immune cells with the goal of killing cancer.
Excited about the possibility of the technology to significantly advance the outcomes for cancer patients, researchers such as Daniel K Conners feel that Biothera is on the forefront of carbohydrate biotechnology and its relevance for a cancer cure.
In addition to developing cancer drugs, Biothera (led by Conners) has an immune health ingredient business based on the same technology platform. It manufactures and markets food-grade (non-pharmaceutical) ingredients for foods, beverages, dietary supplements, cosmetics and animal nutrition. This is a growing business with tremendous opportunities to deliver our immune-enhancing technologies in every day products, said Conners.
Biotheras intellectual property includes more than 40 U.S. patents and patents pending, plus additional patent filings in more than 20 other countries. Currently, with Conners at the helm, the company has more than 50 employees, with over half focused on the research and development of the companys technology platform in the companys labs at its headquarters in Eagan, Minnesota.
Biopolymer Engineering, Inc was founded by Daniel K Conners in 1997 and later renamed Biothera. Biothera now focuses on the manufacturing and improvement of innate complex carbohydrates. Bioploymer Engineering was recognized as a principal in the purification, characterization and production of a variety of carbohydrates. However, Biotheras platform technology carbohydrate predates the company.
According to Conners, researchers at various universities for decades have studied certain carbohydrates in fungi, cereals and bacteria and have identified a link between these polysaccharides and immune activity. But prior to Biothera, no one had successfully delineated the specific mechanism of action these carbohydrates use to effect immune function. - 17269
The entirely new cancer treatment envisioned by Conners so long ago is still being tested in the clinic, but the initial results are attracting serious attention from leading oncologists and pharmaceutical firms. This targeted immunotherapy drug works synergistically with monoclonal antibodies to take on innate immune cells with the goal of killing cancer.
Excited about the possibility of the technology to significantly advance the outcomes for cancer patients, researchers such as Daniel K Conners feel that Biothera is on the forefront of carbohydrate biotechnology and its relevance for a cancer cure.
In addition to developing cancer drugs, Biothera (led by Conners) has an immune health ingredient business based on the same technology platform. It manufactures and markets food-grade (non-pharmaceutical) ingredients for foods, beverages, dietary supplements, cosmetics and animal nutrition. This is a growing business with tremendous opportunities to deliver our immune-enhancing technologies in every day products, said Conners.
Biotheras intellectual property includes more than 40 U.S. patents and patents pending, plus additional patent filings in more than 20 other countries. Currently, with Conners at the helm, the company has more than 50 employees, with over half focused on the research and development of the companys technology platform in the companys labs at its headquarters in Eagan, Minnesota.
Biopolymer Engineering, Inc was founded by Daniel K Conners in 1997 and later renamed Biothera. Biothera now focuses on the manufacturing and improvement of innate complex carbohydrates. Bioploymer Engineering was recognized as a principal in the purification, characterization and production of a variety of carbohydrates. However, Biotheras platform technology carbohydrate predates the company.
According to Conners, researchers at various universities for decades have studied certain carbohydrates in fungi, cereals and bacteria and have identified a link between these polysaccharides and immune activity. But prior to Biothera, no one had successfully delineated the specific mechanism of action these carbohydrates use to effect immune function. - 17269
About the Author:
Discover the Natural push to Cure Cancer at the Cancer Technology Q and A with Mr. Conners web site. Mr. Conners Professional Bio and Info is also available at Biothera and Mr. Conners
posted by X - Men at
7:49 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home